Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate

A technology of magnesium ascorbyl phosphate and sterilized composition, applied in the field of sterilized composition, can solve the problems of reduced stability of composition, unimproved stability and the like

Active Publication Date: 2021-03-23
LABES VIVACY
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] The patent application clearly states that the stability of the composition containing ascorbic acid derivatives is not improved relative to the same composition without ascorbic acid and that the addition of ascorbic acid derivatives can lead to a slight decrease in the stability of the composition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate
  • Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate
  • Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0183] This example illustrates a composition according to the invention comprising non-crosslinked hyaluronic acid and magnesium ascorbyl phosphate.

[0184] Fibers of injectable grade sodium hyaluronate (NaHA) (1 g; molecular weight: about 2.7 MDa) were weighed into a container. An aqueous solution of phosphate buffer (32.3 g) was added and the whole solution was homogenized using a spatula at room temperature and an atmospheric pressure of 900 mmHg for about 1 hour.

[0185] The NaHA content of the non-crosslinked NaHA hydrogel thus obtained was about 30 mg / g.

[0186] Magnesium ascorbyl phosphate (MAP) (60mg or 2.4×10 -4 mol) was dissolved in phosphate buffer (19.94 g) to obtain an aqueous solution of magnesium ascorbyl phosphate with a content of 3 mg / g.

[0187] The NaHA hydrogel obtained in the above step was diluted by adding a previously prepared aqueous solution of magnesium ascorbyl phosphate. Then, the resulting composition was homogenized.

[0188] This gave a...

Embodiment 2

[0191] This example illustrates an example of a composition according to the invention comprising cross-linked hyaluronic acid and magnesium ascorbyl phosphate.

[0192] Starting with fibers of sodium hyaluronate (NaHA) (1 g; molecular weight: about 2.7 MDa) and butanediol diglycidyl ether (BDDE, 54 mg) by the crosslinking method described in WO 2009 / 071697 by VIVACY (Example 1, Part 1) Obtaining a composition comprising cross-linked hyaluronic acid. The resulting composition contained about 30 mg / g of cross-linked NaHA with a degree of cross-linking X of about 0.12.

[0193] According to Example 1, an aqueous solution of magnesium ascorbyl phosphate with a content of 3 mg / g was prepared.

[0194] The cross-linked NaHA hydrogel obtained in the above step was diluted by adding a previously prepared aqueous solution of magnesium ascorbyl phosphate. Then, the resulting composition was homogenized.

[0195] This gave a composition comprising crosslinked NaHA in an amount of 20 ...

Embodiment 3

[0198] This example illustrates an example of a composition according to the invention comprising cross-linked hyaluronic acid, magnesium ascorbyl phosphate and lidocaine.

[0199] Compositions comprising cross-linked NaHA were prepared by the method described in Example 2, starting with NaHA hydrogel at 30 mg / g and magnesium ascorbyl phosphate at 10 mg / g.

[0200] To the composition obtained above was added a solution of lidocaine at a content of 13 mg / g by the method described in WO 2009 / 024670 by ANTEIS or by the method described in patent application US 61 / 791,977 or FR 13 / 52971 by VIVACY.

[0201] The resulting composition contained cross-linked hyaluronic acid in an amount of 20 mg / g, lidocaine in an amount of 3 mg / g and magnesium ascorbyl phosphate in an amount of 1 mg / g; the mass ratio [HA] / [MAP] was 20.

[0202] The composition thus obtained was packaged in autoclaved (T = 121° C., 10 minutes) syringes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
cross-linking degreeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to sterilized compositions comprising at least one hyaluronic acid and magnesium ascorbyl phosphate, in particular to sterilized compositions comprising at least one hyaluronic acid or a biological Pharmaceutically acceptable salts and magnesium ascorbyl phosphate, the mass ratio [HA] / [MAP] of the content of hyaluronic acid or one of its salts [HA] to the content of magnesium ascorbyl phosphate [MAP] is greater than or equal to 1, ascorbic acid The content of magnesium phosphate is from 0.001% to 1% by weight relative to the total weight of the composition, wherein the elastic component G' is maintained or increased after sterilization and is from 5 to 400 Pa. The present invention also relates to a composition according to the invention further comprising dimethyl sulfone, a process for its preparation and its use.

Description

[0001] This application is a divisional application of a Chinese patent application with an application date of August 29, 2013, an application number of 201380045060.9, and an invention title of "sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate". technical field [0002] The present invention relates to a sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate. Background technique [0003] Hyaluronic acid has been used in the cosmetic field for more than fifteen years, where it has proven to be harmless and effective. Currently, the most widely used products in the cosmetic filler gel or filler market are gels based on cross-linked hyaluronic acid from biological fermentation. [0004] The use of hyaluronic acid from biofermentation in fields such as filling wrinkles, viscosupplementation (viscosupplementation), ophthalmic treatment or urinary incontinence treatment is more recognized an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61L27/20A61L27/52A61L27/54A61K8/73A61K8/67A61K8/46A61Q19/08
CPCA61K8/46A61K8/676A61K8/735A61L27/20A61L27/52A61L27/54A61Q19/08A61L2300/216A61K2800/91A61L2300/428A61L2300/41A61L2430/34A61L2400/06C08L5/08C08B37/0072C08K5/41C08K5/529A61K8/447A61K8/55
Inventor 热雷米·邦贝唐埃斯特尔·皮龙
Owner LABES VIVACY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap